Leprosy
or Hansen's disease (HD) is a chronic infection caused by
Mycobacterium lepromatosis or Mycobacterium leprae bacteria. Leprosy
is principally a granulomatous disease. Symptoms of leprosy include
reddish skin lesions, loss of sensation, and weakness of hands and
muscles. Nerve damage is the primary cause for numbness of muscles.
Leprosy is a communicable disease that can be propagated through
contact with cough or phlegm of the affected person. Other risk
factors of leprosy include malnutrition and weak immune system.
Leprosy is especially prevalent in low-income countries.
Get
In-Depth Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/128
Leprosy
Treatment Market Outlook
According
to the statistics received by the World Health Organization (WHO),
from various regions (138 countries), the number of registered cases
of leprosy was 176,176 in 2015, that is 0.18 cases per 10 000 people.
The number of new cases shows the degree of sustained transmission of
the disease. Global statistics illustrate that 203,600 (96%) of fresh
leprosy cases were from 22 key countries. Prevalence of high
occurrences is a reminder that some areas around the world show high
incidences of the disease and experience very high rate of
transmission. According to WHO, around 16 million cases of leprosy
have been treated in the last two decades. Governing bodies and
governments alike are trying to eradicate the presence of the disease
on a global scale. Owing to these factors, the leprosy treatment
market is expected to grow at substantial rate over the forecast
period (2016–2024).
Leprosy
Treatment Market Future Outlook: Asia Pacific to be Key Growth Market
Leprosy has been endemic to mankind since many decades. This needed
interference of various governments around the world as well as the
World Health Organization. Governments play an important role in the
leprosy treatment market. Ever since the introduction of multidrug
therapy by WHO in 1982, governments around the world have adopted
this treatment procedure on a large scale. Some of them subsidized
the treatment to eradicate the presence of the disease from their
countries. Therefore government regulation as well as adoption
remains the most important driver of the leprosy treatment market.
Key
Players in Leprosy Treatment Market -
Companies
operating in the leprosy treatment market include Glaxo Smithcline
Pharmaceuticals Ltd., Systopic Laboratories Pvt. Ltd., Acme
Pharmaceuticals, Cadila Pharmaceuticals, Macleods Pharmaceuticals,
IDPL, Astra Zeneca Pharma India Ltd., Lark Laboratories (UIndia)
Ltd., Genetic Pharma, and Novartis International AG.
Leprosy
Treatment Market Taxonomy -
On
the basis of type of leprosy, the global leprosy treatment market is
classified into:
-
Early and indeterminate leprosy treatment
-
Borderline tuberculoid leprosy treatment
-
Tuberculoid leprosy treatment
-
Borderline leprosy treatment
-
Histoid leprosy treatment
-
Lepromatous leprosy treatment
-
Borderline lepromatous leprosy treatment
-
Diffuse leprosy of Lucio and Latapí
Browse
In-Depth Analysis Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/leprosy-treatment-market-128
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment